{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:32Z","timestamp":1790770112487,"version":"4.1.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibition of the B-cell receptor (BCR) signaling pathway is highly effective in B-cell neoplasia through Bruton tyrosine kinase inhibition by ibrutinib. Ibrutinib also disrupts cell adhesion between a tumor and its microenvironment. However, it is largely unknown how BCR signaling is linked to cell adhesion. We observed that intrinsic sensitivities of mantle cell lymphoma (MCL) cell lines to ibrutinib correlated well with their cell adhesion phenotype. RNA-sequencing revealed that BCR and cell adhesion signatures were simultaneously downregulated by ibrutinib in the ibrutinib-sensitive, but not ibrutinib-resistant, cells. Among the differentially expressed genes, RAC2, part of the BCR signature and a known regulator of cell adhesion, was downregulated at both the RNA and protein levels by ibrutinib only in sensitive cells. RAC2 physically associated with B-cell linker protein (BLNK), a BCR adaptor molecule, uniquely in sensitive cells. RAC2 reduction using RNA interference and CRISPR impaired cell adhesion, whereas RAC2 overexpression reversed ibrutinib-induced cell adhesion impairment. In a xenograft mouse model, mice treated with ibrutinib exhibited slower tumor growth, with reduced RAC2 expression in tissue. Finally, RAC2 was expressed in \u223c65% of human primary MCL tumors, and RAC2 suppression by ibrutinib resulted in cell adhesion impairment. These findings, made with cell lines, a xenograft model, and human primary lymphoma tumors, uncover a novel link between BCR signaling and cell adhesion. This study highlights the importance of RAC2 and cell adhesion in MCL pathogenesis and drug development.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001665","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T05:50:59Z","timestamp":1610344259000},"page":"185-197","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2"],"prefix":"10.1182","volume":"5","author":[{"given":"Wenjun","family":"Wu","sequence":"first","affiliation":[{"name":"Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weige","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China;"},{"name":"Department of Oncology, Fudan University Shanghai Medical School, Shanghai, China;"},{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Franzen","sequence":"additional","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Lee","sequence":"additional","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9481-8086","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Research Informatics, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China;"},{"name":"Department of Oncology, Fudan University Shanghai Medical School, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ming","sequence":"additional","affiliation":[{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Lu","sequence":"additional","affiliation":[{"name":"Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA;"},{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhui","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang Leo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Changying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Andrade","sequence":"additional","affiliation":[{"name":"Center for Research Informatics, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-7237","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China;"},{"name":"Department of Oncology, Fudan University Shanghai Medical School, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1212","authenticated-orcid":false,"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[{"name":"Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA;"},{"name":"Lymphoma Translational Pathology, Department of Pathology, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"2021010622460521300_B1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/asheducation-2015.1.82","article-title":"B-cell receptor pathway modulators in NHL","volume":"2015","author":"Blum","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2021010622460521300_B2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"de Melo Campos","year":"2014","journal-title":"Leuk Res"},{"issue":"9","key":"2021010622460521300_B3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/leu.2008.163","article-title":"Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib","volume":"22","author":"Yang","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2021010622460521300_B4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-09-1519","article-title":"Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib","volume":"16","author":"Song","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2021010622460521300_B5","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2021010622460521300_B6","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2021010622460521300_B7","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Cheng","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2021010622460521300_B8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2021010622460521300_B9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2021010622460521300_B10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2021010622460521300_B11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ng.451","article-title":"In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression","volume":"41","author":"Meacham","year":"2009","journal-title":"Nat Genet"},{"issue":"42","key":"2021010622460521300_B12","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"2021010622460521300_B13","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2021010622460521300_B14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"key":"2021010622460521300_B15","first-page":"2013293087","article-title":"Mutations associated with resistance to inhibitors of Bruton\u2019s tyrosine kinase (BTK)","volume":"LLC","author":"Chang","year":"2014","journal-title":"Pharmacyclices"},{"key":"2021010622460521300_B16","article-title":"BTK mutation and ibrutinib resistance.","author":"Wang","year":"2019"},{"issue":"24","key":"2021010622460521300_bib48","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"2021010622460521300_B17","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2021010622460521300_B18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021010622460521300_B19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2021010622460521300_B20","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2021010622460521300_B21","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","article-title":"Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo","volume":"21","author":"Herman","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2021010622460521300_B22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2013.10.004","article-title":"Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study","volume":"38","author":"Kater","year":"2014","journal-title":"Leuk Res"},{"issue":"12","key":"2021010622460521300_B25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"43","key":"2021010622460521300_B26","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2021010622460521300_B27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/PAS.0000000000000396","article-title":"Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR\/PI3K\/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features","volume":"39","author":"Wang","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2021010622460521300_B44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.0105-2896.2006.00373.x","article-title":"A library of gene expression signatures to illuminate normal and pathological lymphoid biology","volume":"210","author":"Shaffer","year":"2006","journal-title":"Immunol Rev"},{"issue":"12","key":"2021010622460521300_B45","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantel cell lymphoma via nuclear retention of I\u03baB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"2021010622460521300_B46","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma [published correction appears in Blood Adv. 2018;2(20):2588]","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"issue":"134","key":"2021010622460521300_B47","first-page":"57278","article-title":"Highly efficient gene disruption of murine and human hematopoietic progenitor cells by CRISPR\/Cas9","volume":"134","author":"Brunetti","year":"2018","journal-title":"J Vis Exp"},{"issue":"6","key":"2021010622460521300_B28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2021010622460521300_B29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"17","key":"2021010622460521300_B42","doi-asserted-by":"crossref","first-page":"15122","DOI":"10.18632\/oncotarget.3824","article-title":"Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"2021010622460521300_B23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/1940-6207.CAPR-09-0066","article-title":"The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase\/Src signaling mechanism","volume":"2","author":"Franzen","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"2021010622460521300_B24","first-page":"11.13.1","article-title":"RNA-seq data: challenges in and recommendations for experimental design and analysis","volume":"83","author":"Williams","year":"2014","journal-title":"Curr Protoc Hum Genet"},{"issue":"9","key":"2021010622460521300_B30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma [published correction appears in Cancer Discov. 2019;9(11):1629]","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"14","key":"2021010622460521300_B31","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1074\/jbc.272.14.9108","article-title":"Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway","volume":"272","author":"Holland","year":"1997","journal-title":"J Biol Chem"},{"issue":"6","key":"2021010622460521300_B32","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1200\/JCO.1999.17.6.1869","article-title":"Expression of beta-integrin adhesion molecules in non-Hodgkin\u2019s lymphoma: correlation with clinical and evolutive features","volume":"17","author":"Terol","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021010622460521300_B33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V80.2.478.478","article-title":"Induction of CD11a\/leukocyte function antigen-1 and CD54\/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity","volume":"80","author":"Jansen","year":"1992","journal-title":"Blood"},{"issue":"1","key":"2021010622460521300_B34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1083\/jcb.105.1.553","article-title":"Involvement of leukocyte function-associated antigen-1 (LFA-1) in the invasion of hepatocyte cultures by lymphoma and T-cell hybridoma cells","volume":"105","author":"Roos","year":"1987","journal-title":"J Cell Biol"},{"issue":"5","key":"2021010622460521300_B35","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1083\/jcb.108.5.1979","article-title":"Involvement of LFA-1 in lymphoma invasion and metastasis demonstrated with LFA-1-deficient mutants","volume":"108","author":"Roossien","year":"1989","journal-title":"J Cell Biol"},{"issue":"1","key":"2021010622460521300_B36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev.immunol.021908.132554","article-title":"The ins and outs of leukocyte integrin signaling","volume":"27","author":"Abram","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2021010622460521300_B37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.immuni.2007.12.003","article-title":"Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formation","volume":"28","author":"Arana","year":"2008","journal-title":"Immunity"},{"issue":"5644","key":"2021010622460521300_B38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1089709","article-title":"Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling","volume":"302","author":"Walmsley","year":"2003","journal-title":"Science"},{"issue":"1","key":"2021010622460521300_B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(00)80153-3","article-title":"BLNK: connecting Syk and Btk to calcium signals","volume":"12","author":"Kurosaki","year":"2000","journal-title":"Immunity"},{"issue":"2","key":"2021010622460521300_B40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"issue":"20","key":"2021010622460521300_B41","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"issue":"37","key":"2021010622460521300_B43","doi-asserted-by":"crossref","first-page":"24731","DOI":"10.18632\/oncotarget.25340","article-title":"Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma","volume":"9","author":"Yu","year":"2018","journal-title":"Oncotarget"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/1\/185\/1796653\/advancesadv2020001665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/1\/185\/1796653\/advancesadv2020001665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T05:53:20Z","timestamp":1610344400000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/1\/185\/474816\/Inhibition-of-B-cell-receptor-signaling-disrupts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001665","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]}}}